

VirB12 Is a Serological Marker of *Brucella* Infection in Experimental and Natural Hosts[▽]

Hortensia G. Rolán,¹ Andreas B. den Hartigh,¹ Melissa Kahl-McDonagh,² Thomas Ficht,²
L. Garry Adams,² and Renée M. Tsois^{1*}

University of California, Department of Medical Microbiology and Immunology, One Shields Avenue, Davis, California 95616,¹
and Texas A&M University College Of Veterinary Medicine, Department of Veterinary Pathobiology,
College Station, Texas 77843-4467²

Received 18 September 2007/Returned for modification 1 October 2007/Accepted 21 November 2007

The *Brucella* species type IV secretion system, encoded by the *virB1-12* locus, is required for intracellular replication and persistent infection in vivo. The requirement of VirB proteins for infection suggests that they are expressed in vivo and may therefore represent serological markers of infection. To test this idea, we purified recombinant VirB1, VirB5, VirB11, and VirB12 and tested for their recognition by antibodies in sera from experimentally infected mice and goats by using an indirect enzyme-linked immunosorbent assay. Antibody responses to VirB12 but not to VirB1, VirB5, or VirB11 were detected in 20/20 mice experimentally inoculated with *Brucella abortus* and 12/12 goats experimentally infected with *Brucella melitensis*. The potential use of VirB12 as a serological tool for the diagnosis of brucellosis was evaluated in the natural bovine host. Serum samples from 145 cattle of known serology (29% negative and 71% positive) were analyzed for the production of antibody responses to VirB12. One hundred two cattle samples (70.3%) were positive for antibodies to VirB12, while 43 samples were negative (29.7%). A positive serological response to VirB12 correlated with positive serology to whole *B. abortus* antigen in 99% of samples tested. These results show that VirB12 is expressed during infection of both experimental and natural hosts of *Brucella* species, and they suggest that VirB12 may be a useful serodiagnostic marker for brucellosis.

Brucella strains are the causative agents of brucellosis, which can affect both animals and humans. The disease is characterized by bacterial persistence in the reticuloendothelial system, including the liver, spleen, and lymph nodes, and infection may result in abortion in infected ruminants (34). Zoonotic transmission of the bacteria to humans is caused by accidental contamination from unpasteurized animal products or infected animals.

The type IV secretion system (T4SS) is encoded by the *virB* locus, located on chromosome II, and includes *virB1* to *virB12* (2, 3). The T4SS of *Brucella* spp. has been shown to be an essential virulence factor, and T4SS mutants are highly attenuated in tissue culture models of intracellular survival, in the mouse model of persistent infection (3, 5–8, 10, 14, 23, 30, 32), and in the goat, a natural host for *Brucella melitensis* (12). A functional T4SS is not required for initial colonization in mice but is required for evasion of immune responses activated during the first week of infection (25, 27).

Several diagnostic tools are used for the detection of brucellosis. While bacteriological isolation is the most specific diagnostic test, the frequency of isolation is usually low, and results are not available immediately. For this reason, serological tests are widely used for diagnosis of human and animal brucellosis (1). Classical serological techniques rely on the

detection of smooth lipopolysaccharide (LPS), but false-positive reactions may occur due to cross-reactivity with LPS from other bacteria (21, 22, 33). The shortcomings of the classical serological tests have sparked increasing interest in finding alternative antigens to detect brucellosis.

Secreted or cell envelope-associated bacterial proteins are often antigenic in the context of infection. Proteins associated with the cell envelope of *Brucella* species have previously been shown to elicit antibody responses in both experimentally and naturally infected animals (4, 17–19, 24, 26). Further, VirB proteins from other bacteria, including *Ehrlichia canis* and *Anaplasma marginale*, have been shown to be immunogenic (9, 20). Since the *Brucella abortus* T4SS has been shown to be expressed during infection and encodes an apparatus that assembles at the surface of the cell, we tested whether the components of the T4SS apparatus are immunogenic and whether responses to these proteins can be used as serological indicators of infection with *Brucella* species. We have previously shown that mice infected with *B. abortus* 2308 produced an antibody response to the protein encoded by the *virB12* gene (31). In this study, we used purified recombinant VirB1, VirB5, VirB11, and VirB12 to assess the antibody responses to these proteins in sera from mice experimentally infected with *B. abortus*, from goats experimentally infected with *B. melitensis*, and from cattle of known serological status for *Brucella*.

* Corresponding author. Mailing address: Department of Medical Microbiology and Immunology, University of California, One Shields Avenue, Davis, CA 95616. Phone: (530) 754-8497. Fax: (530) 754-7240. E-mail: rmtsois@ucdavis.edu.

[▽] Published ahead of print on 12 December 2007.

MATERIALS AND METHODS

Bacterial strains, media, and culture conditions. *Escherichia coli* cultures were grown on Luria-Bertani (Difco, Becton Dickinson, Sparks, MD) plates or in Luria-Bertani broth at 37°C with or without antibiotics. *Brucella abortus* 2308,

TABLE 1. Bacterial strains and plasmids

Strain or plasmid	Relevant characteristic(s)	Source or reference
Strains		
<i>E. coli</i> BL21(DE3)	F' <i>ompT gal [dcm] [lon] hsdS_B(r_B⁻ m_B⁻)</i> DE3	29
<i>Brucella abortus</i>		
2308	Bovine isolate	B. Deyoe
ADH4	Δ <i>virB1-12::Km</i>	8
<i>Brucella melitensis</i>		
16M	Wild type	13
BM Δ <i>asp24</i>	Δ <i>asp24</i>	13
BM Δ <i>virB2</i>	Δ <i>virB2</i> (nonpolar)	13
BM Δ <i>cydBA</i>	Δ <i>cydBA</i>	12
Plasmids		
pGEX-4T-2	Ap ^r , N-terminal GST tag, <i>lacI</i> ^q	Pharmacia
pAV5.1	VirB5 cloned into pGEX-4T-1	8
pMO4	VirB1 cloned into pGEX-4T-2	8
pIVEX2.4bNdeI	Ap ^r , T7 promoter, N-terminal six-His tag	Roche
pDS1	VirB12 cloned into pIVEX2.4bNdeI	31
pT7-7Strep::VirB11	VirB11 cloned into pT7-7Strep	11

Brucella melitensis 16M, and isogenic mutant strains were cultured on tryptic soy agar (Difco, Becton Dickinson, Sparks, MD) or in tryptic soy broth at 37°C on a rotary shaker. Their characteristics are listed in Table 1. Bacterial inocula for infection of mice were cultured on tryptic soy agar plus 5% blood. All work with live *Brucella* species was performed at biosafety level 3.

Infection of mice. Female C57BL/6J and BALB/c ByJ mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and used at the ages of 8 to 10 weeks. Mice were held in microisolator cages with sterile bedding and water and irradiated feed in a biosafety level 3 facility. For infection experiments, groups of 10 to 20 mice were inoculated intraperitoneally with 0.1 ml of phosphate-buffered saline (PBS) containing 5 × 10⁵ CFU of *B. abortus* 2308 or an isogenic Δ *virB1-12* mutant (complete deletion of the *virB* locus). Ten age-matched mice were injected with PBS. For assaying specific antibody responses, blood samples were collected from the saphenous vein before infection (infected mice) and once a week for 10 weeks after infection for both infected and PBS-treated mice. All animal experiments were approved by the Texas A&M University Laboratory Animal Care and Use Committee and were conducted in accordance with institutional guidelines.

Goat serum samples. Twelve serum samples from experimentally infected goats were used in this study. Animals were infected, and sera were collected, as described previously by us (12). Briefly, female Angora goats averaging 110 days of gestation were infected at 1 × 10⁷ CFU via bilateral conjunctival inoculation, and sera were collected 8 weeks after infection. Goats (three per group) were infected with *B. melitensis* 16M or the BM Δ *asp24*, BM Δ *virB2* (nonpolar), or BM Δ *cydBA* isogenic mutant. Serum samples from 12 naive goats were also used.

Bovine serum samples. One hundred forty-five serum samples of known serology (as determined by the brucellosis card test and an enzyme-linked immunosorbent assay [ELISA] with whole *Brucella* antigen) were used in this study. One hundred three seropositive samples were from the investigators' specimen collection. The 42 known negative samples were obtained from male calves housed at a dairy calf-rearing operation in Texas, since male dairy calves are not vaccinated against brucellosis.

Purification of GST-VirB1 and GST-VirB5. *E. coli* BL21 carrying pMO4 (glutathione *S*-transferase [GST]-VirB1) or *E. coli* BL21 carrying pAV5.1 (GST-VirB5) was grown in 20 ml of LB containing 100 µg/liter of carbenicillin (LB plus Carb) at 37°C. Expression of GST-VirB1 or GST-VirB5 was induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 37°C. Bacteria were resuspended in 1 ml of PBS buffer containing 2% Tween 20 and protease inhibitor cocktail (Sigma). Cells were lysed by sonication and centrifuged, and the supernatant was

mixed with 2 ml of glutathione Sepharose 4B (Amersham Bioscience, Piscataway, NJ) beads and incubated for 1 h at 4°C. The slurry was transferred to a column and washed three times with cold PBS. The protein was eluted by adding 1 ml of elution buffer (0.031 g reduced glutathione in 10 ml of 10 mM Tris-HCl [pH 8.0]). GST-VirB1 and GST-VirB5 were concentrated using Amicon Ultra-15 (Millipore) concentration tubes.

Removal of the GST tag from VirB1 and VirB5. To avoid measuring serological responses to the GST moiety of GST fusion proteins, the GST tag was removed from GST-VirB1 and GST-VirB5 by incubation with thrombin at room temperature for 2 h. The reaction mixture was mixed with 1 ml of glutathione Sepharose 4B (Amersham Bioscience, Piscataway, NJ) beads and incubated for 1 h at 4°C. The slurry was transferred to a column and washed once with cold PBS (the wash contained the protein of interest). VirB1 and VirB5 were concentrated using Amicon Ultra-15 (Millipore) concentration tubes and were dialyzed twice against PBS (pH 7.4).

Purification of recombinant VirB11. Strep-VirB11 was purified according to the manufacturer's (IBA, Germany) protocol. Briefly, *E. coli* BL21 carrying pT7-7Strep::*virB11* was grown for 16 h in 2 liters of LB plus Carb at 37°C. On the following day, expression of Strep-VirB11 was induced with 1 mM IPTG for 16 h at room temperature. Bacteria were resuspended in 40 ml of washing buffer with 0.5 mM phenylmethylsulfonyl fluoride. Bacteria were lysed with a French press and pelleted twice at 11,000 rpm, and the supernatant was transferred to a 5-ml column of streptactin beads (IBA) that was equilibrated with 2 column volumes (CV) of buffer W (100 mM Tris-HCl [pH 8], 150 mM NaCl, 1 mM EDTA). The beads were washed twice with 5 CV of buffer W, and the protein was eluted with 6 × 0.5 CV buffer E (buffer W plus 2.5 mM desthiobiotin). Strep-VirB11 was concentrated using Amicon Ultra-15 (Millipore) concentration tubes and was dialyzed twice against PBS (pH 7.4).

Purification of recombinant VirB12. *E. coli* BL21 carrying pDS1 (His₆-VirB12) was grown in 20 ml of LB plus Carb at 37°C. Expression of His₆-VirB12 was induced with 1 mM IPTG at 37°C. VirB12 was purified under denaturing conditions using reagents from Qiagen (Valencia, CA). Briefly, after induction, cells were lysed with lysis buffer (100 mM NaH₂PO₄, 10 mM Tris-HCl, 8 M urea [pH 8.0]), passed through a column, washed with wash buffer (100 mM NaH₂PO₄, 10 mM Tris-HCl, 8 M urea [pH 6.3]), and eluted with elution buffer (100 mM NaH₂PO₄, 10 mM Tris-HCl, 8 M urea [pH 4.5]). VirB12 was concentrated using Amicon Ultra-15 (Millipore) concentration tubes and was dialyzed twice against PBS, pH 7.4.

Detection of VirB12-specific IgG in serum samples. The presence of antibody specific for the recombinant *B. abortus* VirB12 protein in the sera of mice, goats, and cattle was determined by an indirect ELISA. Nickel-nitrilotriacetic acid HisSorb plates from Qiagen (Valencia, CA) were coated with 100 ng of His-VirB12 per well in carbonate buffer (pH 9.6), and plates were incubated at 4°C overnight. After a wash with PBS and 0.05% Tween 20 (PBS-T), mouse serum samples (1:100), goat serum samples (1:16,000), or bovine serum samples (1:16,000) were diluted in PBS-B for mouse samples (PBS, 0.05% Tween 20, and 2% bovine serum albumin) or PBS-G for goat and bovine samples (PBS, 0.05% Tween 20, and 2% gelatin) and were incubated at 37°C for 1 h. After a wash with PBS-T, the reactivity was measured using horseradish peroxidase-conjugated anti-mouse (1:1,000; BD Pharmingen), anti-goat (1:5,000; Jackson ImmunoResearch), or anti-bovine (1:5,000; Jackson ImmunoResearch) immunoglobulin G (IgG) by incubating the plates at 37°C for 1 h. The reaction was developed with Sigma Fast *o*-phenylenediamine dihydrochloride tablet sets. The resulting color was read at 450 nm with an ELISA microplate reader (Bio-Rad model 680). Data points are the averages of duplicate dilutions, and each measurement was performed twice.

Detection of VirB1-specific, VirB5-specific, and VirB11-specific IgG. The presence of antibody specific for the recombinant proteins VirB1, VirB5, and VirB11 of *Brucella abortus* in the sera of mice, goats, and cattle was determined by ELISA. MaxiSorp plates from Qiagen (Valencia, CA) were coated with 100 ng of VirB1, VirB5, or VirB11 per well in carbonate buffer (pH 9.6), and plates were incubated at 4°C overnight. ELISA was performed as described above. Data points are the averages of duplicate dilutions, and each measurement was performed twice.

Detection of Brucella-specific IgG. The presence of antibody specific for whole-cell antigen of *B. abortus* in the sera of mice, goats, and cattle was determined by ELISA. MaxiSorp plates from Qiagen (Valencia, CA) were coated with 100 µl formalin-killed whole *B. abortus* (1 µg/ml) in carbonate buffer (pH 9.6), and plates were incubated at 4°C overnight. Mouse serum samples were diluted 1:100, while goat and cattle samples were measured at a dilution of 1:16,000. ELISAs were performed as described above. Data points are the averages of duplicate dilutions, and each measurement was performed twice.




FIG. 1. Detection of anti-VirB antibodies in sera from mice experimentally infected with wild-type *Brucella abortus* 2308 or its $\Delta virB1-12$ isogenic mutant. Ten to 20 mice were infected intraperitoneally with 2308 or a $\Delta virB1-12$ mutant. Blood was collected before infection and 9 weeks after infection. Ten age-matched mice were treated with PBS, and blood was collected 9 weeks later. Antibodies specific for VirB1, VirB5, VirB11, and VirB12 (α -VirB1, α -VirB5, α -VirB11, and α -VirB12) were detected by ELISA. Data are presented as the A_{450} of a 1:100 dilution of serum. Each bar indicates the average \pm standard deviation of triplicate samples. ND, not determined. Asterisk indicates statistical significance, determined by Student's *t* test. A *P* value of <0.05 was considered significant.

Brucellosis card test. To check the serology status of the goat and cattle samples, the brucella card test (obtained from National Veterinary Service Laboratories, Ames, IA) was performed according to the manufacturers' recommendations.

Statistical analysis. For determination of statistical significance between experimental groups and naïve groups, Student's *t* test was performed on the data. A *P* value of <0.05 was considered significant.

RESULTS

***B. abortus*-infected mice develop antibody responses specific for VirB12 but not for VirB1, VirB5, or VirB11.** To determine whether VirB1, VirB5, VirB11, and VirB12 can serve as serological markers of infection with *Brucella* spp., we assayed the antibody responses of infected mice for IgG specific for VirB1, VirB5, VirB11, and VirB12. Serum samples were obtained from mice infected with either *B. abortus* 2308 or the $\Delta virB1-12$ mutant (a mutant strain carrying a complete deletion of the *virB* locus) or from age-matched uninfected controls. We have previously shown that for *B. abortus*-infected mice, the level of IgG specific for VirB12 increased over that for naïve mice starting at 3 weeks after infection (with the highest response at weeks 8 to 10), while that for mice infected with a $\Delta virB12$ mutant (in which only *virB12* was deleted) did not differ from the preinoculation level (31). The results in Fig. 1 show that at week 9 after infection, levels of IgG-specific for VirB1, VirB5, and VirB11 in preinfection samples or samples from naïve age-matched mice did not differ from those for mice infected with either 2308 or the $\Delta virB1-12$ mutant. When mice were infected with the $\Delta virB1-12$ mutant, levels of VirB12-specific IgG did not differ from those in preinfection samples or age-matched naïve mice. VirB12-specific IgG levels did, however, increase in mice infected with *B. abortus* 2308 (wild type) over those in naïve mice, as previously described (31). These results indicate that VirB12 elicits an antibody response during infection of mice, while VirB1, VirB5, and VirB11 do not.

VirB12, but not VirB1, VirB5, or VirB11, is immunogenic in goats. To determine whether VirB1, VirB5, VirB11, and VirB12 elicited antibody responses in a natural host for *Brucella*, we obtained sera from 12 goats experimentally infected with *B. melitensis* 16M or its isogenic mutant $\Delta asp24$,

BM $\Delta virB2$ (nonpolar), or BM $\Delta cydBA$ (12) and sera from 12 naïve goats. The levels of IgG specific for VirB1 (Fig. 2A), VirB11 (Fig. 2B), or VirB5 (Fig. 2C) determined by ELISA did not differ between naïve goats and goats infected with either wild-type *B. melitensis* 16M or any of the mutant strains. In contrast, for all four groups of animals infected with *B. melitensis* strains, the levels of IgG-specific for VirB12 (Fig. 2D) increased significantly above those measured for naïve goats. These results indicate that VirB12 is expressed in vivo and generates a host response during infection of goats, while VirB1, VirB5, and VirB11 do not appear to elicit antibody responses.

To correlate serological responses to VirB12 with responses to whole-cell antigen, we performed ELISA on the goat serum samples using whole-cell *Brucella* antigen (Fig. 3A). The serology response to *Brucella* IgG was confirmed with the brucellosis card test. Goats infected with *B. melitensis* $\Delta virB2$ (nonpolar) did not exhibit IgG responses to whole-cell *Brucella* antigen, while for goats infected with 16M or the $\Delta asp24$ mutant and for two of the goats infected with the $\Delta cydBA$ mutant, anti-*Brucella* IgG levels increased over those for naïve controls, in agreement with previous results reported by Kahl-McDonagh et al. (12).

The correlation between levels of IgG specific for whole-cell *Brucella* antigen and VirB12-specific IgG is shown in Fig. 3B. Three goats infected with *B. melitensis* $\Delta virB2$ and one goat infected with *B. melitensis* $\Delta cydBA$ did not develop high levels of *Brucella*-specific IgG antibody but produced high levels of anti-VirB12 antibody. The remaining infected goats generated both a high *Brucella*-specific IgG response and a high VirB12-specific response. For all 12 infected goats, positive antibody responses to VirB12 were observed.

Cattle seropositive for *Brucella* also develop an immune response to VirB12. To explore the potential of VirB12 as a serological marker of infection in cattle, we measured VirB12-specific IgG by ELISA in 145 cattle samples of known *B. abortus* serology (Fig. 4). We obtained 42 seronegative and 103 seropositive samples. In serum samples from 102 cattle, IgG specific for VirB12 was detected, with a mean A_{450} of $0.792 \pm$




FIG. 2. Analysis of anti-VirB (α -VirB) antibodies in sera from 12 goats experimentally infected with wild-type *B. melitensis* 16M or one of its isogenic mutants BM Δ virB2, BM Δ asp24, or BM Δ cydBA and from 12 uninfected controls. Blood was collected 8 weeks after infection, and levels of IgG specific for VirB1, VirB5, VirB11, and VirB12 in serum were determined by ELISA. Data are presented as the A_{450} of a 1:16,000 dilution of serum. Each bar indicates the average \pm standard deviation for three goats per infected group assayed in triplicate. The uninfected group contains 12 goats. The horizontal line in each graph represents the background reactivity of uninfected goats. Asterisks indicate statistically significant differences between groups of infected and naive goats, determined by Student's *t* test. A *P* value of <0.05 was considered significant.

0.221. For the 43 cattle samples showing no response to VirB12, the mean A_{450} was 0.061 ± 0.046 . The correlation between IgG responses specific for *Brucella* whole-cell antigen and for VirB12 is shown in Fig. 4. One hundred two samples (70.3%) were serologically positive for both *Brucella* and VirB12. Forty-two samples (29%) were serologically negative for both whole-cell antigen and VirB12. One animal (0.7%) showed a seropositive result for whole *Brucella* antigen, but no VirB12-specific IgG was detected. Overall, serological results for whole-cell antigen and VirB12 were concordant for 99% of samples.

DISCUSSION

This study was undertaken to determine whether individual proteins encoded by the *virB* locus, which assemble to form a secretion apparatus at the surface of the bacterium, are immunogenic and whether serological responses to these proteins can be used for detection of brucellosis.

We purified recombinant VirB1, VirB5, VirB11, and VirB12 antigens and evaluated their potential use for the serological diagnosis of brucellosis by ELISA. Evidence of VirB12 expression (Fig. 1) was detected in mice infected with *B. abortus*: an IgG response specific for VirB12 was elicited after infection with *B. abortus* 2308 but not after infection with a mutant lacking the entire *virB* locus. The cell surface localization of VirB12 may contribute to its immunogenicity, as well as the

fact that it is a predicted lipoprotein. VirB1, VirB5, and VirB11 also assemble in the membrane of the bacterium (16, 28), but we could not find evidence of specific antibody response against these proteins in the mouse or the goat model. One possible explanation for this result that we cannot exclude is that the recombinant VirB1, VirB5, and VirB11 antigens used for indirect ELISA were not in their native conformations, which would negatively impact the performance of our detection assay. However, a lack of immunogenicity of VirB1 and VirB5 could benefit *Brucella* during infection, since in the closely related bacterium *Agrobacterium tumefaciens*, these two proteins have been shown to be part of a pilus structure that protrudes from the bacterial surface and is therefore exposed to the immune system (15).

The BM Δ asp24, BM Δ virB2, and BM Δ cydBA mutants used in our study have been assessed as vaccine candidates in the goat and mouse models of infection (12, 13). Both the BM Δ asp24 and BM Δ virB2 mutants have shown promise as safe vaccine candidates in mouse and goat models. BM Δ asp24 was able to colonize the maternal tissues but not the fetal tissues and cause seroconversion in goats, while BM Δ virB2 was not capable of colonizing maternal or fetal tissues and did not cause seroconversion. The BM Δ cydBA mutant was as virulent in the pregnant goat model as 16M (12).

Goats infected with *B. melitensis* 16M or the BM Δ asp24, BM Δ virB2, or BM Δ cydBA mutant elicited a response specific for VirB12, but not for VirB1, VirB5, or VirB11. BM Δ virB2 is




FIG. 3. (A) *Brucella*-specific (α -*Brucella*) IgG in sera from 12 goats experimentally infected with wild-type *Brucella melitensis* 16M or its isogenic mutant BM Δ virB2, BM Δ asp24, or BM Δ cydBA and from 12 uninfected controls. Blood was collected 8 weeks after infection, and levels of *Brucella*-specific IgG in serum samples were determined by ELISA and the brucellosis card test. Data are presented as the A_{450} of a 1:16,000 dilution of serum. Each bar indicates the average \pm standard deviation for 3 goats per infected group or 12 goats per uninfected group, assayed in triplicate. Asterisks indicate that differences between groups of infected and naïve goats, determined by Student's *t* test, are statistically significant. A *P* value of <0.05 was considered significant. (B) Correlation between *Brucella*-specific IgG and VirB12-specific (α -VirB12) IgG in goats. Each dot represents both the level of *Brucella*-specific IgG and the level of *Brucella*-specific anti-VirB12 for one goat. Horizontal and vertical lines represent the background reactivities for uninfected goats (A_{450} , 0.2). Data points above the dashed line represent goats with positive card test results, while points below this line represent animals with negative card test results.

a nonpolar mutation of VirB2; thus, VirB3 to VirB12 are expected to be expressed during infection (8). Goats infected with BM Δ virB2 did not seroconvert to whole-cell *Brucella* antigen (Fig. 3) (12) but exhibited a strong VirB12 response. One of the goals for the development of vaccines and diagnostic

tools for brucellosis is a test that can distinguish between vaccinated and naturally infected animals. Our results show the potential of using VirB12 for such a goal, since BM Δ virB2 was found to be a safe vaccine with no seroconversion by using the brucellosis card test and whole-cell ELISA but elicited an




FIG. 4. Analysis of anti-VirB12 (α -VirB12) IgG and *Brucella*-specific (α -*Brucella*) IgG in sera from cattle infected with *Brucella abortus*. The lines represent the background reactivities for uninfected and unvaccinated cattle, as determined by ELISA and the brucellosis card test. Data are presented as the A_{450} of a 1:16,000 dilution of serum.

elevated VirB12 response when an ELISA with recombinant purified VirB12 was used to assay infection.

A second goal of the present study was to assess the potential diagnostic utility of VirB12 in natural hosts of *Brucella*. We obtained 145 cattle serum samples of known serology (42 seronegative [29%] and 103 seropositive [71%]). Serology status was checked by both the brucellosis card test and whole-cell *Brucella* antigen ELISA.

As shown in Fig. 4, antibodies to VirB12 were detected in 70.3% (102 of 145) of bovine serum samples tested, while 29.7% of the samples did not give a response to VirB12. One of the 145 cattle samples was serologically positive for *Brucella* but negative for antibodies specific to VirB12. Serological tests for brucellosis may yield false-positive results for cattle vaccinated with *B. abortus* S19 or exposed to gram-negative bacteria with LPS O-chains similar to those of *Brucella*, such as *Yersinia enterocolitica* O:9. The cross-reactivity between *Y. enterocolitica* O:9 and *Brucella* is due to a strong similarity of the LPS O-chains (21, 33). We do not know if this animal showed serological reactivity to *Brucella* due to cross-reactivity with *Y. enterocolitica* O:9 or other bacteria, such as *E. coli* O157:H7, a frequent colonizer of cattle. Since we did not detect seroreactivity to VirB12, either this animal may have been infected and did not respond to VirB12 or it had a serological cross-reaction to whole cells elicited by bacteria other than *Brucella*. Based on the information at hand, we are unable to distinguish between these two possibilities.

In summary, this study shows that antibodies to *B. abortus* VirB12 can be identified in mice, goats, and cattle. One hundred percent of the experimentally infected mice and goats generated specific responses to VirB12, including those infected with mutants shown to be promising vaccine candidates (12, 13). These results encourage further investigation with patient samples to determine whether detection of humoral responses to VirB12-specific immune responses can be used for the diagnosis of human brucellosis.

ACKNOWLEDGMENTS

We thank C. Baron for providing pT7-7Strep::VirB11.

This work was supported by PHS award U54 AI057156 to L.G.A., T.F., and R.M.T. and by PHS award AI050553 to R.M.T.

REFERENCES

- Araj, G. F. 1999. Human brucellosis: a classical infectious disease with persistent diagnostic challenges. *Clin. Lab. Sci.* **12**:207–212.
- Boschiroli, M. L., S. Ouahrani-Bettache, V. Foulongne, S. Michaux-Charachon, G. Bourg, A. Allardet-Servent, C. Cazeville, J. P. Lavigne, J. P. Liautard, M. Ramuz, and D. O'Callaghan. 2002. Type IV secretion and *Brucella* virulence. *Vet. Microbiol.* **90**:341–348.
- Boschiroli, M. L., S. Ouahrani-Bettache, V. Foulongne, S. Michaux-Charachon, G. Bourg, A. Allardet-Servent, C. Cazeville, J. P. Liautard, M. Ramuz, and D. O'Callaghan. 2002. The *Brucella suis* virB operon is induced intracellularly in macrophages. *Proc. Natl. Acad. Sci. USA* **99**:1544–1549.
- Cassataro, J., K. Pasquevich, L. Bruno, J. C. Wallach, C. A. Fossati, and P. C. Baldi. 2004. Antibody reactivity to Omp31 from *Brucella melitensis* in human and animal infections by smooth and rough brucellae. *Clin. Diagn. Lab. Immunol.* **11**:111–114.
- Celli, J., C. de Chastellier, D. M. Franchini, J. Pizarro-Cerda, E. Moreno, and J. P. Gorvel. 2003. *Brucella* evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. *J. Exp. Med.* **198**:545–556.
- Comerci, D. J., M. J. Martinez-Lorenzo, R. Sieira, J. P. Gorvel, and R. A. Ugalde. 2001. Essential role of the VirB machinery in the maturation of the *Brucella abortus*-containing vacuole. *Cell. Microbiol.* **3**:159–168.
- Delrue, R. M., M. Martinez-Lorenzo, P. Lestrade, I. Danese, V. Bielarz, P. Mertens, X. De Bolle, A. Tibor, J. P. Gorvel, and J. J. Letesson. 2001. Identification of *Brucella* spp. genes involved in intracellular trafficking. *Cell. Microbiol.* **3**:487–497.
- den Hartigh, A. B., Y. H. Sun, D. Sondervan, N. Heuvelmans, M. O. Reinders, T. A. Ficht, and R. M. Tsolis. 2004. Differential requirements for VirB1 and VirB2 during *Brucella abortus* infection. *Infect. Immun.* **72**:5143–5149.
- Felek, S., H. Huang, and Y. Rikihisa. 2003. Sequence and expression analysis of virB9 of the type IV secretion system of *Ehrlichia canis* strains in ticks, dogs, and cultured cells. *Infect. Immun.* **71**:6063–6067.
- Hong, P. C., R. M. Tsolis, and T. A. Ficht. 2000. Identification of genes required for chronic persistence of *Brucella abortus* in mice. *Infect. Immun.* **68**:4102–4107.
- Höppner, C., A. Carle, D. Sivanesan, S. Hoëppner, and C. Baron. 2005. The putative lytic transglycosylase VirB1 from *Brucella suis* interacts with the type IV secretion system core components VirB8, VirB9 and VirB11. *Microbiol. J.* **151**:3469–3482.
- Kahl-McDonagh, M. M., P. H. Elzer, S. D. Hagius, J. V. Walker, Q. L. Perry, C. M. Seabury, A. B. den Hartigh, R. M. Tsolis, L. G. Adams, D. S. Davis, and T. A. Ficht. 2006. Evaluation of novel *Brucella melitensis* unmarked deletion mutants for safety and efficacy in the goat model of brucellosis. *Vaccine* **24**:5169–5177.
- Kahl-McDonagh, M. M., and T. A. Ficht. 2006. Evaluation of protection afforded by *Brucella abortus* and *Brucella melitensis* unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. *Infect. Immun.* **74**:4048–4057.
- Kim, S., M. Watarai, Y. Kondo, J. Erdenebaatar, S. Makino, and T. Shirahata. 2003. Isolation and characterization of mini-Tn5Km2 insertion mutants of *Brucella abortus* deficient in internalization and intracellular growth in HeLa cells. *Infect. Immun.* **71**:3020–3027.
- Lai, E.-M., and C. I. Kado. 2000. The T-pilus of *Agrobacterium tumefaciens*. *Trends Microbiol.* **8**:361–369.
- Lai, E. M., and C. I. Kado. 1998. Processed VirB2 is the major subunit of the promiscuous pilus of *Agrobacterium tumefaciens*. *J. Bacteriol.* **180**:2711–2717.
- Letesson, J. J., A. Tibor, G. van Eynde, V. Wansard, V. Weynants, P. Denoel, and E. Saman. 1997. Humoral immune responses of *Brucella*-infected cattle, sheep, and goats to eight purified recombinant *Brucella* proteins in an indirect enzyme-linked immunosorbent assay. *Clin. Diagn. Lab. Immunol.* **4**:556–564.
- Limet, J. N., A. Cloeckert, G. Bezard, J. Van Broeck, and G. Dubray. 1993. Antibody response to the 89-kDa outer membrane protein of *Brucella* in bovine brucellosis. *J. Med. Microbiol.* **39**:403–407.
- Lindler, L. E., T. L. Hadfield, B. D. Tall, N. J. Snellings, F. A. Rubin, L. L. Van De Verg, D. Hoover, and R. L. Warren. 1996. Cloning of a *Brucella melitensis* group 3 antigen gene encoding Omp28, a protein recognized by the humoral immune response during human brucellosis. *Infect. Immun.* **64**:2490–2499.
- Lopez, J. E., G. H. Palmer, K. A. Brayton, M. J. Dark, S. E. Leach, and W. C. Brown. 2007. Immunogenicity of *Anaplasma marginale* type IV secretion system proteins in a protective outer membrane vaccine. *Infect. Immun.* **75**:2333–2342.
- Mittal, K. R., I. R. Tizard, and D. A. Barnum. 1985. Serological cross-reactions between *Brucella abortus* and *Yersinia enterocolitica* O:9. *Int. J. Zoonoses* **12**:219–227.
- Nielsen, K., P. Smith, J. Widdison, D. Gall, L. Kelly, W. Kelly, and P. Nicoletti. 2004. Serological relationship between cattle exposed to *Brucella abortus*, *Yersinia enterocolitica* O:9 and *Escherichia coli* O157:H7. *Vet. Microbiol.* **100**:25–30.
- O'Callaghan, D., C. Cazeville, A. Allardet-Servent, M. L. Boschiroli, G. Bourg, V. Foulongne, P. Frutos, Y. Kulakov, and M. Ramuz. 1999. A homologue of the *Agrobacterium tumefaciens* VirB and *Bordetella pertussis* Ptl type IV secretion systems is essential for intracellular survival of *Brucella suis*. *Mol. Microbiol.* **33**:1210–1220.
- Pugh, G. W., Jr., L. B. Tabatabai, B. J. Bricker, J. E. Mayfield, M. Phillips, E. S. Zehr, and C. A. Belzer. 1990. Immunogenicity of *Brucella*-extracted and recombinant protein vaccines in CD-1 and BALB/c mice. *Am. J. Vet. Res.* **51**:1413–1420.
- Rolán, H. G., and R. M. Tsolis. 2007. Mice lacking components of adaptive immunity show increased *Brucella abortus* virB mutant colonization. *Infect. Immun.* **75**:2965–2973.
- Rossetti, O. L., A. I. Arese, M. L. Boschiroli, and S. L. Cravero. 1996. Cloning of *Brucella abortus* gene and characterization of expressed 26-kilodalton periplasmic protein: potential use for diagnosis. *J. Clin. Microbiol.* **34**:165–169.
- Roux, C. M., H. G. Rolán, R. L. Santos, P. D. Beremand, T. L. Thomas, L. G. Adams, and R. M. Tsolis. 2007. *Brucella* requires a functional type IV secretion system to elicit innate immune responses in mice. *Cell. Microbiol.* **9**:1851–1869.
- Schmidt-Eisenlohr, H., N. Domke, C. Angerer, G. Wanner, P. C. Zambryski, and C. Baron. 1999. Vir proteins stabilize VirB5 and mediate its association with the T pilus of *Agrobacterium tumefaciens*. *J. Bacteriol.* **181**:7485–7492.
- Studier, F. W., and B. A. Moffatt. 1986. Use of bacteriophage T7 RNA

- polymerase to direct selective high-level expression of cloned genes. *J. Mol. Biol.* **189**:113–130.
30. Sun, Y. H., A. B. den Hartigh, R. L. Santos, L. G. Adams, and R. M. Tsois. 2002. *virB*-mediated survival of *Brucella abortus* in mice and macrophages is independent of a functional inducible nitric oxide synthase or NADPH oxidase in macrophages. *Infect. Immun.* **70**:4826–4832.
 31. Sun, Y. H., H. G. Rolán, A. B. den Hartigh, D. Sondervan, and R. M. Tsois. 2005. *Brucella abortus virB12* is expressed during infection but is not an essential component of the type IV secretion system. *Infect. Immun.* **73**: 6048–6054.
 32. Watarai, M., S. Makino, and T. Shirahata. 2002. An essential virulence protein of *Brucella abortus*, VirB4, requires an intact nucleoside-triphosphate-binding domain. *Microbiology* **148**:1439–1446.
 33. Weynants, V., A. Tibor, P. A. Denoel, C. Saegerman, J. Godfroid, P. Thiange, and J. J. Letesson. 1996. Infection of cattle with *Yersinia enterocolitica* O:9 a cause of the false positive serological reactions in bovine brucellosis diagnostic tests. *Vet. Microbiol.* **48**:101–112.
 34. Young, E. 2000. *Brucella* species, p. 2386–2393. In G. Mandel, J. Bennett, and R. Dolin (ed.), *Mandell, Douglas, and Bennett's principles and practice of infectious diseases*, vol. 2. Churchill Livingstone, Philadelphia, PA.